Takeda

AMGEN PRESENTS NEW SCIENTIFIC AND CLINICAL RESEARCH ACROSS ITS DIVERSE ONCOLOGY PORTFOLIO AND PIPELINE AT ASCO 2023

Retrieved on: 
Thursday, June 1, 2023
AMGN, KRAS, Amgen, KID, Osteoporosis, Research and development, Plasma, RAS, Patient, Panitumumab, Blinatumomab, Myelodysplastic syndrome, Carcinoma, CT, Bi-specific T-cell engager, Multiple myeloma, Panama, Lenalidomide, Lung cancer, MRD, Heath Robinson (codebreaking machine), Inotuzumab ozogamicin, Docetaxel, Abstract, Metastasis, RCT, Cancer, Carfilzomib, NSCLC, Denosumab, Sarcoma, Colorectal cancer, Biomarker, Busulfan, Neoplasm, Pembrolizumab, CRC, Dexamethasone, SCLC, ASCO, Talimogene laherparepvec, American Society of Clinical Oncology, ASCT, Melanoma, Annual general meeting, CDT, Melphalan, Society, Pharmaceutical industry, Medical imaging, Communications satellite, Flour, Glass wool, Vaccine, Nursing, Book, Takeda, Allotransplantation, Research

THOUSAND OAKS, Calif., June 1, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new scientific and clinical research across its diverse oncology portfolio and pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from June 2-6 in Chicago. More than 25 abstracts from Amgen-sponsored and collaborative studies, including three oral presentations and two poster discussions, will feature data in hard-to-treat tumor types, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and small cell lung cancer (SCLC).

Key Points: 
  • Additional Analyses from DeLLphi-300 Highlight Safety and Clinical Efficacy of Tarlatamab, an Investigational First-in-Class BiTE® Immunotherapy, in Patients with SCLC With Treated and Stable Brain Metastases
    THOUSAND OAKS, Calif., June 1, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new scientific and clinical research across its diverse oncology portfolio and pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from June 2-6 in Chicago.
  • More than 25 abstracts from Amgen-sponsored and collaborative studies, including three oral presentations and two poster discussions, will feature data in hard-to-treat tumor types, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and small cell lung cancer (SCLC).
  • "Our presentations at ASCO will illustrate how we're advancing novel approaches to address the toughest thoracic and colorectal cancers with limited treatment options," said David M. Reese, M.D., executive vice president of Research and Development at Amgen.
  • "We're focused on expanding the reach and impact of our transformative, first-in-class medicines to help more people living with cancer."

Takeda Opens Digital Health Innovation Challenge in Partnership with Plug and Play Alberta for Solutions to Improve Patient Care in Inflammatory Bowel Disease

Retrieved on: 
Thursday, June 1, 2023
Partnership, Crohn's disease, Bureau of Oceans and International Environmental and Scientific Affairs, Health, IBD, HCP, Patient, Ulcerative colitis, Physician, Artificial intelligence, Digital, Inflammatory bowel disease, Plug and play, CIRC, Pharmaceutical industry, Nursing, Takeda

In the second challenge, Takeda is collaborating with Plug and Play Alberta ("Plug and Play") to help broaden our reach and to harness their expertise in connecting innovative tech initiatives with large corporations to propel digital transformation.

Key Points: 
  • In the second challenge, Takeda is collaborating with Plug and Play Alberta ("Plug and Play") to help broaden our reach and to harness their expertise in connecting innovative tech initiatives with large corporations to propel digital transformation.
  • This year's challenge looks to identify best-in-class solutions with the potential to improve the patient or health care provider (HCP) experience in Inflammatory Bowel Disease (IBD), the most common forms being Ulcerative Colitis and Crohn's Disease.
  • "We are thrilled to launch our second Takeda Canada Digital Health Innovation Challenge.
  • The Takeda Canada Digital Health Innovation Challenge application period runs June 1 through June 24, 2023.

Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review

Retrieved on: 
Friday, May 26, 2023
Disease, CRC, Progression-free survival, TAK, New Drug Application, JAMA, NDA, American Medical Association, VEGF, Journal, Patient, PDUFA, BSC, Phase, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, HCM, Food, Pharmaceutical industry, Takeda

OSAKA, Japan and CAMBRIDGE, Mass. and HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 25, 2023 (GLOBE NEWSWIRE) -- Takeda (TSE:4502/NYSE:TAK) and HUTCHMED (China) Limited (Nasdaq/AIM:HCM, HKEX:13) (“HUTCHMED”) today announced that the U.S. Food and Drug Administration (“FDA”) has granted priority review of the New Drug Application (“NDA”) for fruquintinib, a highly selective and potent inhibitor of vascular endothelial growth factor receptors (“VEGFR”) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (“CRC”). If approved, fruquintinib will be the first and only highly selective inhibitor of all three VEGF receptors approved in the U.S. for previously treated metastatic CRC.1,2 The Prescription Drug User Fee Act (PDUFA) goal date assigned by the FDA for this NDA is November 30, 2023.

Key Points: 
  • — Prescription Drug User Fee Act (PDUFA) Target Action Date set for November 30, 2023 —
    OSAKA, Japan and CAMBRIDGE, Mass.
  • “We are confident that fruquintinib has the potential to transform the treatment landscape for those living with previously treated metastatic colorectal cancer, as demonstrated by its strong clinical profile,” said Awny Farajallah, M.D., head of Global Medical Affairs Oncology at Takeda.
  • “The clinical benefit of fruquintinib has been confirmed in multiple ways, from global clinical studies to commercialization in China.
  • “Today’s acceptance marks a significant advancement towards the goal of providing patients with previously treated metastatic colorectal cancer a much-needed therapeutic option, given the limited treatment options currently available to patients.

Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review

Retrieved on: 
Thursday, May 25, 2023
Research, FDA, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Disease, CRC, Progression-free survival, TAK, New Drug Application, JAMA, NDA, PFS, American Medical Association, VEGF, Journal, Patient, VEGFR, PDUFA, BSC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, HCM, Food, Pharmaceutical industry, Takeda

Takeda ( TSE:4502/NYSE:TAK ) and HUTCHMED (China) Limited (Nasdaq/AIM:HCM, HKEX:13) ( HUTCHMED ) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review of the New Drug Application (NDA) for fruquintinib, a highly selective and potent inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (CRC).

Key Points: 
  • Takeda ( TSE:4502/NYSE:TAK ) and HUTCHMED (China) Limited (Nasdaq/AIM:HCM, HKEX:13) ( HUTCHMED ) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review of the New Drug Application (NDA) for fruquintinib, a highly selective and potent inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (CRC).
  • “We are confident that fruquintinib has the potential to transform the treatment landscape for those living with previously treated metastatic colorectal cancer, as demonstrated by its strong clinical profile,” said Awny Farajallah, M.D., head of Global Medical Affairs Oncology at Takeda.
  • “The clinical benefit of fruquintinib has been confirmed in multiple ways, from global clinical studies to commercialization in China.
  • “Today’s acceptance marks a significant advancement towards the goal of providing patients with previously treated metastatic colorectal cancer a much-needed therapeutic option, given the limited treatment options currently available to patients.

Sinaptica Appoints Ken Mariash as Chief Executive Officer

Retrieved on: 
Wednesday, May 24, 2023
Mental Health, Medical Devices, FDA, Seniors, Clinical Trials, Biotechnology, Health, Consumer, General Health, University of Oxford, Therapy, CSL Behring, Marketing, Baxter, Pathology, Business, Business economics, CRA International, EBT, Multimedia, Strategic planning, Economics, Amyloid, HIV disease progression rates, Patient, Oxford University Press, Neuromodulation, Investment, Associate, Brown University, System, Overactive bladder, R, AD, Medtech, Memory, BD, Pharmaceutical industry, Takeda, Boston Scientific, Biochemistry, Brain

Sinaptica Therapeutics, Inc ., a clinical-stage company leading the development of a new class of personalized neuromodulation therapeutics to treat Alzheimer’s and neurodegenerative diseases, announces the appointment of Ken Mariash Jr. as Chief Executive Officer.

Key Points: 
  • Sinaptica Therapeutics, Inc ., a clinical-stage company leading the development of a new class of personalized neuromodulation therapeutics to treat Alzheimer’s and neurodegenerative diseases, announces the appointment of Ken Mariash Jr. as Chief Executive Officer.
  • As Chief Executive Officer, Mariash joins the company to accelerate clinical product development of the company’s SinaptiStim™ System, a closed-loop neuromodulation therapy that utilizes a novel approach to treating AD by enhancing neuroplasticity via neurostimulation of key brain networks involved in memory.
  • “As Sinaptica prepares for a pivotal clinical trial of our closed-loop neuromodulation therapy, Ken is the ideal choice to lead the company through this important stage,” said Rich Macary, President of Sinaptica Therapeutics.
  • Prior to EBT, Mariash was Director, Strategy and New Markets for the nearly $1B Neuromodulation division of Boston Scientific.

Takeda to Present Oncology Portfolio and Pipeline Data at the 2023 ASCO Annual Meeting and EHA Congress

Retrieved on: 
Friday, May 26, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, CRC, European Hematology Association, TAK, Cancer, Head, Research, NSCLC, ASCO, Hypodiploid acute lymphoblastic leukemia, Congress, Hematological Cancer Research Investment and Education Act, Takeda Oncology, Patient, Colorectal cancer, EHA, Society, TSE, Medical imaging, Takeda

Takeda (TSE: 4502/NYSE:TAK) today announced that it will present data from its expanding oncology pipeline and established product portfolio at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held June 2-6, 2023, in Chicago, Ill. and the 31st Congress of the European Hematology Association (EHA), June 8-11, 2023, in Frankfurt, Germany.

Key Points: 
  • Takeda (TSE: 4502/NYSE:TAK) today announced that it will present data from its expanding oncology pipeline and established product portfolio at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held June 2-6, 2023, in Chicago, Ill. and the 31st Congress of the European Hematology Association (EHA), June 8-11, 2023, in Frankfurt, Germany.
  • The company’s presence at ASCO 2023 will underscore Takeda’s growing solid tumor portfolio, with research focused on improving treatment for metastatic colorectal cancer (CRC), as well as rare forms of oncogene-driven non-small cell lung cancer (NSCLC).
  • Within its hematology portfolio, Takeda will present data in oral sessions at both ASCO and EHA on a head-to-head Phase 3 study comparing targeted treatments in newly diagnosed patients with Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
  • Building on decades of leadership in oncology and a portfolio of approved medicines for hematologic cancers and solid tumors, we are advancing a cutting-edge pipeline focused on the power of innate immunity.

Global Pharma and Biotech Clinical Stage Partnering Analysis Report 2023 with a Directory Containing Terms and Agreements for 2,900+ Deals - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 23, 2023
Health, Pharmaceutical, GSK, Amgen, Actavis, Intellectual property, Baxter, Roche, A-Z, Record, Research, Confidentiality, AstraZeneca, Eli Lilly, J&J, Biotechnology, Kyowa Kirin, Bausch Health, Novartis, Merck, Biogen, BMS, Hyperlink, Pharmaceutical industry, Commercial property, Vaccine, Risk management, Lease, Property management, Pharma, Teva, Astellas Pharma, Takeda, Bayer, Pfizer

The "Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2016-2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2016-2023" report has been added to ResearchAndMarkets.com's offering.
  • The Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2016 - 2023 report provides comprehensive access to available deals and contract documents for over 2,900 clinical stage deals.
  • The report provides a detailed understanding and analysis of how and why companies enter clinical stage partnering deals and provides details of the latest clinical agreements announced in the healthcare sector.
  • Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2016 - 2023 includes:
    In Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2016 - 2023, the available contracts are listed by:
    Analyzing actual contract agreements allows assessment of the following:
    What are the precise rights granted or optioned?

Reltio Unveils Out-of-the-Box Solutions for Financial Services and Insurance Organizations to Speed Digital Transformation Initiatives

Retrieved on: 
Tuesday, May 23, 2023
Professional Services, Data Management, Technology, Insurance, Finance, Fintech, Banking, Consultant, Data management, Software as a service, Partnership, Master data management, KYB, Financial services, Marketing, Health care, Research, AstraZeneca, Xerox, TCS, Organization, Name, CarMax, Automation, Knowledge, MDM, Growth, ROI, SVP, KYC, Velocity, Cryptocurrency, Risk management, Video game, Bank, Takeda, Head, Pfizer

Now, Reltio is helping companies in banking, asset management, investment services, and insurance jumpstart their digital transformation journeys and speed time to value with tailored solutions and pre-packaged configurations, integrations and implementation assets specific to their industries.

Key Points: 
  • Now, Reltio is helping companies in banking, asset management, investment services, and insurance jumpstart their digital transformation journeys and speed time to value with tailored solutions and pre-packaged configurations, integrations and implementation assets specific to their industries.
  • Velocity packs offer an intuitive experience, low-code / no-code integration tooling, and unique delivery methodology to further speed time to value.
  • “With our tailored solutions for financial services and insurance companies and unique delivery methodology, our customers are consuming and activating trusted, unified data in less than 90 days.
  • Reltio for Financial Services and Reltio for Insurance velocity packs include three core elements to help businesses bring their MDM projects to life more quickly:
    An out-of-the-box, customizable data model specifically tailored to financial services and insurance organizations.

CASIO ENHANCES CLASSPAD.NET TO IMPROVE USER EXPERIENCE

Retrieved on: 
Tuesday, May 23, 2023
Learning, Senior, Education, Takeda, Feedback, Web browser, Android, IOS, Nature, International Physics and Culture Olympiad, Student, Love, Casio, Physics, Mathematics, Mac, Tutoring

DOVER, N.J., May 23, 2023 /PRNewswire/ -- As the education landscape continues to evolve, educators are increasingly adopting digital learning platforms to support student learning and foster their academic growth. Keeping this in mind, Casio America, Inc. sought out and incorporated real feedback from educators when upgrading its popular, award-winning, web-based platform ClassPad.net. While math can be a challenging subject to broach for many students, ClassPad.net engages students in unique ways to help further their education, while also supporting educators.

Key Points: 
  • Keeping this in mind, Casio America, Inc. sought out and incorporated real feedback from educators when upgrading its popular, award-winning, web-based platform ClassPad.net .
  • "Casio recognizes how invaluable educators are, and we understand that utilizing educators' feedback is of the utmost importance when updating our programming."
  • We are committed to not only maintain but continually evolve ClassPad.net based on user feedback that we receive," said Takeda.
  • By co-sponsoring this event, Casio hopes to promote the use of scientific calculators in educational settings in order to support worldwide education.

Kymera Appoints Jeremy Chadwick, Ph.D., as Chief Operating Officer

Retrieved on: 
Monday, May 22, 2023
University, Data management, BS, Senior, Statistics, Simon de Montfort, 6th Earl of Leicester, TPD, Research, Doctor of Philosophy, Sequah Medicine Company, Shire (pharmaceutical company), Patient, Vertex Pharmaceuticals, United Kingdom, Biostatistics, Therapy, Takeda Pharmaceutical Company, Fine chemical, Medical device, Mathematics, Takeda

WATERTOWN, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today announced the appointment of Jeremy Chadwick, Ph.D., as Chief Operating Officer.

Key Points: 
  • WATERTOWN, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today announced the appointment of Jeremy Chadwick, Ph.D., as Chief Operating Officer.
  • Dr. Chadwick joins Kymera with extensive experience overseeing global development operations, regulatory and program management at a range of biopharmaceutical companies.
  • As a member of the Company’s senior management team, Dr. Chadwick will develop and execute near-term and long-range strategies to maximize the impact of Kymera’s expanding pipeline.
  • He earned his MS and PhD in Statistics from the University of London and a BS in Mathematics from Demontfort University in the United Kingdom.